We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
- Authors
Wierda, William G.; Johnson, Marcella M.; Do, Kim-Anh; Manshouri, Taghi; Dey, Amanda; O'Brien, Susan; Giles, Francis J.; Kantarjian, Hagop; Thomas, Deborah; Faderl, Stefan; Lerner, Susan; Keating, Michael; Albitar, Maher
- Abstract
Summary. The malignant B cells of patients with chronic lymphocytic leukaemia (CLL) constitutively express interleukin 8 (IL-8) and IL-8 receptors. Ex vivo culture with exogenous IL-8 enhances IL-8 expression and prolongs leukaemia cell survival, partly through increased bcl-2 expression. IL-8 may function as an autocrine growth and apoptosis resistance factor in CLL. Therefore, we evaluated the prognostic relevance of plasma IL-8 levels in 151 CLL patients [median age 61 years (range, 32–84 years), median plasma IL-8 level 18·9 pg/ml (9·1–89·1 pg/ml)]. All Rai stages were represented; advanced stage was associated with significantly higher plasma IL-8 levels (P < 0·0001, Kruskal–Wallis). Also, plasma IL-8 level was correlated with serum β2-microglobulin (β2-M) (R = 0·24, P = 0·0081), haemoglobin (R = -0·39, P < 0·0001) and platelet count (R = -0·23, P = 0·0049) by Spearman's rank correlation. Univariate analysis using Cox proportional hazards models identified elevated IL-8 and β2-M as significant prognostic factors with relative risks of 7·43 (P = 9·1 × 10-9 ) and 16·40 (P = 5·9 × 10-10 ) respectively. High levels of IL-8 were associated with shorter survival independent of β2-M level. Using recursive-partitioning procedures, an IL-8 cut-off point of 26·2 pg/ml segregated a group of CLL patients with significantly shorter survival (median 9·3 months) (P < 0·0001). In conclusion, plasma IL-8 level in CLL patients correlates with other prognostic factors, such as Rai stage and β2-M, and is associated with increased risk of death in CLL patients. The role of IL-8 inhibitors in the treatment of patients with CLL should be explored.
- Subjects
INTERLEUKIN-8; LYMPHOCYTIC leukemia
- Publication
British Journal of Haematology, 2003, Vol 120, Issue 3, p452
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1046/j.1365-2141.2003.04118.x